Equity Overview
Price & Market Data
Price: $1.60
Daily Change: -$0.09 / 5.62%
Daily Range: $1.59 - $1.71
Market Cap: $101,575,384
Daily Volume: 303,823
Performance Metrics
1 Week: 4.55%
1 Month: 9.52%
3 Months: 9.52%
6 Months: -43.51%
1 Year: -57.96%
YTD: -50.46%
Company Details
Employees: 341
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.